Literature DB >> 10750587

Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease.

B H Lorell1.   

Abstract

Angiotensin II modulates beat-to-beat cardiac performance as a potent vasocontrictor, inotrope, and regulator of water and electrolyte balance. It is also a growth factor that can stimulate the early molecular growth responses of proto-oncogene activation and new protein synthesis, and the later event of cardiocyte hypertrophy independent from load. Its effects are mediated through the angiotensin II type 1 (AT1) receptor, which exists as the AT1a and AT1b isoforms, and the angiotensin II type 2 (AT2) receptor. There is still controversy regarding the role of activation of the AT1 receptor subtype(s) as a mandatory signal versus modulatory regulator of the transduction of mechanical load in pressure-overload hypertrophy due to hypertension or aortic stenosis. The role of the AT2 receptor subtype in the heart is even less well understood, although this receptor appears to serve as an antigrowth signal in proliferating cells. Here we review current data on these controversies, including new data that support the notion that angiotensin II activation of the cardiac AT2 receptor subtype inhibits the effects of angiotensin II on the immediate growth response in the adult heart.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10750587     DOI: 10.1016/s0002-9149(99)00258-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.

Authors:  Mark A Perazella; John F Setaro
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

2.  Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan--a proteomic analysis.

Authors:  Li Liu; Wen Wang; Xianmin Meng; Jiuming Gao; Haiying Wu; Peihe Wang; Weichun Wu; Linlin Wang; Liyuan Ma; Weiguo Zhang
Journal:  J Physiol Biochem       Date:  2010-08-10       Impact factor: 4.158

Review 3.  The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors:  G Neil Thomas; Paul Chan; Brian Tomlinson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure.

Authors:  Maria D Avila; James P Morgan; Xinhua Yan
Journal:  J Biomed Biotechnol       Date:  2011-04-27

5.  Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor.

Authors:  Eric E Essick; Flora Sam
Journal:  Int J Hypertens       Date:  2011-05-22       Impact factor: 2.420

6.  Mild exercise along with limb blood-flow restriction modulates the electrocardiogram, angiotensin, and apelin receptors of the heart in aging rats.

Authors:  Alireza Raji-Amirhasani; Siyavash Joukar; Vida Naderi-Boldaji; Mohammad-Abbas Bejeshk
Journal:  Iran J Basic Med Sci       Date:  2018-06       Impact factor: 2.699

7.  Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments.

Authors:  Kristina Yeghiazaryan; Dirk Skowasch; Gerhard Bauriedel; Hans H Schild; Olga Golubnitschaja
Journal:  EPMA J       Date:  2011-04-03       Impact factor: 6.543

8.  Angiotensin type 1a receptor signaling is not necessary for the production of reactive oxygen species in polymorphonuclear leukocytes.

Authors:  Fumiko Yamato; Junji Takaya; Shoji Tsuji; Masafumi Hasui; Kazunari Kaneko
Journal:  ISRN Inflamm       Date:  2012-12-04

9.  Src is required for mechanical stretch-induced cardiomyocyte hypertrophy through angiotensin II type 1 receptor-dependent β-arrestin2 pathways.

Authors:  Shijun Wang; Hui Gong; Guoliang Jiang; Yong Ye; Jian Wu; Jieyun You; Guoping Zhang; Aijun Sun; Issei Komuro; Junbo Ge; Yunzeng Zou
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.